$MNKD
MANNKIND CORP

2018 Q1 Form 10-Q Financial Statement

#000156459018012419 Filed on May 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $3.465M $3.009M
YoY Change 15.15%
Cost Of Revenue $4.008M $2.548M
YoY Change 57.3% -50.7%
Gross Profit -$543.0K $461.0K
YoY Change -217.79% -108.92%
Gross Profit Margin -15.67% 15.32%
Selling, General & Admin $20.62M $15.39M
YoY Change 33.98% 109.35%
% of Gross Profit 3338.18%
Research & Development $2.644M $3.129M
YoY Change -15.5% -39.01%
% of Gross Profit 678.74%
Depreciation & Amortization $400.0K $400.0K
YoY Change 0.0% -33.33%
% of Gross Profit 86.77%
Operating Expenses $23.26M $18.52M
YoY Change 25.62% -7.47%
Operating Profit -$26.79M -$19.60M
YoY Change 36.66% -2.05%
Interest Expense -$5.800M $1.800M
YoY Change -422.22% -136.73%
% of Operating Profit
Other Income/Expense, Net -$3.596M $3.278M
YoY Change -209.7% -167.45%
Pretax Income -$30.39M -$16.32M
YoY Change 86.14% -34.37%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$30.39M -$16.32M
YoY Change 86.14% -34.37%
Net Earnings / Revenue -876.91% -542.51%
Basic Earnings Per Share -$0.25 -$0.17
Diluted Earnings Per Share -$0.25 -$0.17
COMMON SHARES
Basic Shares Outstanding 120.9M 95.74M
Diluted Shares Outstanding 120.9M 95.74M

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.70M $48.00M
YoY Change -44.38% 73.29%
Cash & Equivalents $27.23M $47.98M
Short-Term Investments
Other Short-Term Assets $2.900M $4.000M
YoY Change -27.5% -75.46%
Inventory $3.900M $3.698M
Prepaid Expenses
Receivables $1.550M $438.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $35.03M $56.09M
YoY Change -37.55% 27.07%
LONG-TERM ASSETS
Property, Plant & Equipment $26.48M $28.48M
YoY Change -7.03% -40.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $368.0K $609.0K
YoY Change -39.57% -44.43%
Total Long-Term Assets $26.85M $29.09M
YoY Change -7.71% -40.79%
TOTAL ASSETS
Total Short-Term Assets $35.03M $56.09M
Total Long-Term Assets $26.85M $29.09M
Total Assets $61.88M $85.19M
YoY Change -27.36% -8.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.976M $1.519M
YoY Change 227.58% 161.0%
Accrued Expenses $15.93M $10.66M
YoY Change 49.48% 31.94%
Deferred Revenue
YoY Change
Short-Term Debt $43.70M $71.80M
YoY Change -39.14% -4.27%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $80.67M $93.05M
YoY Change -13.3% -62.66%
LONG-TERM LIABILITIES
Long-Term Debt $96.60M $77.20M
YoY Change 25.13% -47.12%
Other Long-Term Liabilities $107.8M $113.7M
YoY Change -5.19% 613.03%
Total Long-Term Liabilities $204.4M $190.9M
YoY Change 7.07% 1097.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $80.67M $93.05M
Total Long-Term Liabilities $204.4M $190.9M
Total Liabilities $285.1M $283.9M
YoY Change 0.41% -39.17%
SHAREHOLDERS EQUITY
Retained Earnings -$2.883B -$2.754B
YoY Change 4.7% -4.65%
Common Stock $2.660B $2.555B
YoY Change 4.11% 1.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$223.2M -$198.7M
YoY Change
Total Liabilities & Shareholders Equity $61.88M $85.19M
YoY Change -27.36% -8.67%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$30.39M -$16.32M
YoY Change 86.14% -34.37%
Depreciation, Depletion And Amortization $400.0K $400.0K
YoY Change 0.0% -33.33%
Cash From Operating Activities -$21.65M $8.510M
YoY Change -354.41% -127.67%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $16.65M
YoY Change -100.0% 83150.0%
Cash From Investing Activities $0.00 $16.65M
YoY Change -100.0% -1573.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $634.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 528.0K -80.00K
YoY Change -760.0% -117.39%
NET CHANGE
Cash From Operating Activities -21.65M 8.510M
Cash From Investing Activities 0.000 16.65M
Cash From Financing Activities 528.0K -80.00K
Net Change In Cash -21.12M 25.08M
YoY Change -184.22% -179.8%
FREE CASH FLOW
Cash From Operating Activities -$21.65M $8.510M
Capital Expenditures $0.00
Free Cash Flow $8.510M
YoY Change -126.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
527000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
4409000
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1550000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2789000
CY2018Q1 mnkd Purchase Obligation Current
PurchaseObligationCurrent
15859000
CY2017Q4 us-gaap Inventory Net
InventoryNet
2657000
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2354000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
35028000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26481000
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
368000
CY2018Q1 us-gaap Assets
Assets
61877000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4976000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15930000
CY2018Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
43654000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3038000
CY2017Q4 mnkd Deferred Collaborative Credit Current
DeferredCollaborativeCreditCurrent
250000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
80669000
CY2018Q1 mnkd Purchase Obligation Noncurrent
PurchaseObligationNoncurrent
96694000
CY2018Q1 mnkd Deferred Collaborative Credit Noncurrent
DeferredCollaborativeCreditNoncurrent
437000
CY2017Q4 mnkd Deferred Collaborative Credit Noncurrent
DeferredCollaborativeCreditNoncurrent
500000
CY2018Q1 mnkd Milestone Rights Liability
MilestoneRightsLiability
7201000
CY2017Q4 mnkd Milestone Rights Liability
MilestoneRightsLiability
7201000
CY2018Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3402000
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1196000
CY2018Q1 mnkd Net Revenue From Collaboration
NetRevenueFromCollaboration
63000
CY2017Q1 mnkd Net Revenue From Collaboration
NetRevenueFromCollaboration
63000
CY2017Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
1750000
CY2018Q1 us-gaap Sales Revenue Net
SalesRevenueNet
3465000
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
3009000
CY2018Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
4008000
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
2548000
CY2018Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2644000
CY2017Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3129000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20618000
CY2018Q1 mnkd Deferred Collaborative Credit Current
DeferredCollaborativeCreditCurrent
250000
CY2018Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
72247000
CY2017Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
79666000
CY2018Q1 mnkd Accrued Interest Noncurrent
AccruedInterestNoncurrent
3469000
CY2017Q4 mnkd Accrued Interest Noncurrent
AccruedInterestNoncurrent
2347000
CY2018Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
24368000
CY2017Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
24411000
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
1260000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2658957000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1192000
CY2017Q4 mnkd Purchase Obligation Current
PurchaseObligationCurrent
12131000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
87597000
CY2017Q4 mnkd Purchase Obligation Noncurrent
PurchaseObligationNoncurrent
97585000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2638992000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2883410000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2854898000
CY2018Q1 us-gaap Liabilities
Liabilities
285085000
CY2017Q4 us-gaap Liabilities
Liabilities
299307000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126013051
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119053414
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126013051
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119053414
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-214732000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61877000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84575000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-223208000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
55000
CY2018Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1794000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1545000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
30254000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
22611000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26789000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19602000
CY2017Q1 mnkd Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
6629000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
106000
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15389000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-2984000
CY2017Q1 mnkd Interest On Note Payable To Related Party
InterestOnNotePayableToRelatedParty
714000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2675000
CY2018Q1 mnkd Interest On Note Payable To Related Party
InterestOnNotePayableToRelatedParty
1122000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1077000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1575000
CY2018Q1 us-gaap Increase Decrease In Customer Advances And Deposits
IncreaseDecreaseInCustomerAdvancesAndDeposits
-63000
CY2017Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
2706000
CY2018Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1114000
CY2017Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
714000
CY2018Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-825000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3596000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3278000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30385000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16324000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-30385000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-16324000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
120911000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95744000
CY2018Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
3000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30382000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16324000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
706000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
908000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1943000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1267000
CY2018Q1 us-gaap Production Related Impairments Or Charges
ProductionRelatedImpairmentsOrCharges
602000
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-110000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1128000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
136000
CY2017Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-30557000
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1836000
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1367000
CY2017Q1 mnkd Increase Decrease In Other Deferred Charges
IncreaseDecreaseInOtherDeferredCharges
163000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-656000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-856000
CY2018Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-38000
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-39000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2008000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1665000
CY2017Q1 us-gaap Increase Decrease In Customer Advances And Deposits
IncreaseDecreaseInCustomerAdvancesAndDeposits
-63000
CY2018Q1 mnkd Increase Decrease In Purchase Commitment Loss
IncreaseDecreaseInPurchaseCommitmentLoss
-147000
CY2017Q1 mnkd Increase Decrease In Purchase Commitment Loss
IncreaseDecreaseInPurchaseCommitmentLoss
-534000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21650000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
8507000
CY2017Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
16651000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
16651000
CY2018Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
81000
CY2017Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
75000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
634000
CY2018Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
25000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
528000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-75000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-21122000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
25083000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48355000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22895000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27233000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47978000
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
1860000
CY2017Q1 us-gaap Interest Paid Net
InterestPaidNet
2550000
CY2018Q1 us-gaap Stock Issued1
StockIssued1
9407000
CY2018Q1 mnkd Payments Of Note Payable To Related Party Through Common Stock Issuance
PaymentsOfNotePayableToRelatedPartyThroughCommonStockIssuance
8160000
CY2018Q1 mnkd Debt Issuance Costs Related To Note Payable To Related Party Accrued But Not Yet Paid
DebtIssuanceCostsRelatedToNotePayableToRelatedPartyAccruedButNotYetPaid
75000
CY2018Q1 us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition &#8211; Net Revenue &#8211; Commercial Product Sales &#8211;<font style="font-style:normal;"> The Company sells Afrezza to a limited number of wholesale distributors and specialty pharmacies in the U.S. (collectively, its &#8220;Customers&#8221;). </font><font style="color:#000000;font-style:normal;">These Customers subsequently resell the Company&#8217;s products to retail pharmacies and certain medical centers or hospitals. Specialty pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#8217;s products.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue on product sales when the Customer obtains control of the Company's product, which occurs at a point in time (based on the terms of the relevant contracts which are at delivery for wholesale distributors and at shipment for specialty pharmacies).&nbsp;&nbsp;Product revenues are recorded net of applicable reserves for variable consideration, including discounts and allowances.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Voucher Program &#8211; <font style="font-style:normal;">Under the voucher program, potential new patients are given vouchers which they can provide to retailers for a free product. </font><font style="font-style:normal;color:#000000;"> The retailers provide the product to the patient for free and pay the wholesaler for the product, who pays the Company.&nbsp;&nbsp;The retailers submit the vouchers to a program administrator which pays the retailer for the product.&#160; The administrator then invoices the Company for the amount of vouchers paid plus a fee. Accordingly, on a net basis, it is not probable that the Company will receive the consideration to which it is entitled for these products.&nbsp;&nbsp;Therefore, the Company excludes such amounts from both gross and net revenue.&nbsp;&nbsp;The cost of product associated with the voucher program is included in cost of goods sold.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reserves for Variable Consideration <font style="font-style:normal;">&#8212; Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payors, and other indirect customers relating to the Company&#8217;s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability.&nbsp;&nbsp;</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#8217;s analyses also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of March 31, 2018 and, therefore, the transaction price was not reduced further during the three months ended March 31, 2018. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net revenue &#8211; commercial product sales and earnings in the period such variances become known.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Trade Discounts and Allowances <font style="font-style:normal;">&#8212; The Company generally provides Customers with discounts which include incentive fees, such as prompt pay discounts, that are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and a reduction to accounts receivable, net. </font></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Product Returns <font style="font-style:normal;">&#8212; Consistent with industry practice, the Company generally offers Customers a right of return</font><font style="font-style:normal;color:#000000;"> for unopened product that has been purchased from the Company for a period beginning six months prior to and ending twelve months after its expiration date</font><font style="font-style:normal;">, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company currently estimates that 2.46% of products will be returned.&nbsp;&nbsp;</font></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Provider Chargebacks and Discounts <font style="font-style:normal;">&#8212; Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customer&#8217;s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Government Rebates <font style="font-style:normal;">&#8212; The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Payor Rebates <font style="font-style:normal;">&#8212; The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Incentives <font style="font-style:normal;">&#8212; Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, prior to the adoption of Topic 606, the ending balance for net deferred revenue, was $3.0&#160;million, on the Company&#8217;s condensed consolidated balance sheets which is presented net of $1.5&#160;million in gross-to-net revenue adjustments. On January 1, 2018, deferred revenue was adjusted to zero as a result of the adoption of Topic 606 as disclosed below. For the three months ended March 31, 2018 and 2017, shipments to three wholesale distributors represented 87% and 93% of total shipments, respectively.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
CY2018Q1 us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition &#8211; Net Revenue &#8211; Collaborations <font style="font-style:normal;">&#8212; The Company enters into out-licensing agreements under which the Company licenses certain rights to its product candidates to third parties. </font><font style="color:#000000;font-style:normal;">The terms of these arrangements may include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. Each of these payments may result in license, collaboration, or other revenue, except revenue from royalties on net sales of licensed products, which would be classified as royalty revenue.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success.</p></div>
CY2018Q1 us-gaap Revenue Recognition Sales Of Services
RevenueRecognitionSalesOfServices
<div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Manufacturing Supply Services <font style="font-style:normal;">&#8212; Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply, at the customer&#8217;s discretion, are generally considered as options. The Company assesses if these options provide a material right to the licensee and, if so, they are accounted for as separate performance obligations. If the Company is entitled to additional payments when the licensee exercises these options, any additional payments are recorded in license, collaboration, or other revenue when the customer obtains control of the goods, which is upon delivery.</font></p></div>
CY2018Q1 us-gaap Revenue Recognition Services Royalty Fees
RevenueRecognitionServicesRoyaltyFees
<div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties <font style="font-style:normal;">&#8212; For licensing arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied). For sales of intellectual property that include sales-based royalties, the Company estimates the amount of variable consideration that it will receive from the sales-based royalty. The Company has not recognized any royalty revenue resulting from the sale of its intellectual property in 2017 which is more fully described in Note 9, Sale of Intellectual Property.</font></p></div>
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1007000
CY2017Q1 mnkd Percentage Of Product Shipments To Wholesale Distributors
PercentageOfProductShipmentsToWholesaleDistributors
0.93
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41326151
CY2018Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
140200000
CY2017Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
140000000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
700000000
CY2018Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company’s board of directors approved a 1-for-5 reverse stock split of its outstanding common stock. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, prior to March 3, 2017, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
CY2018Q1 mnkd Number Of Wholesale Distributors
NumberOfWholesaleDistributors
3
CY2017Q1 mnkd Number Of Wholesale Distributors
NumberOfWholesaleDistributors
3
CY2018Q1 mnkd Percentage Of Product Shipments To Wholesale Distributors
PercentageOfProductShipmentsToWholesaleDistributors
0.87
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17237029
CY2018Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
2019000
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
2842000
CY2018Q1 mnkd Wholesaler Distribution Fees And Prompt Pay Discounts
WholesalerDistributionFeesAndPromptPayDiscounts
340000
CY2017Q4 mnkd Wholesaler Distribution Fees And Prompt Pay Discounts
WholesalerDistributionFeesAndPromptPayDiscounts
53000
CY2018Q1 mnkd Reserve For Returns
ReserveForReturns
129000
CY2018Q1 mnkd Percentage Of Accounts Receivable From Major Customers
PercentageOfAccountsReceivableFromMajorCustomers
0.90
CY2017Q4 mnkd Percentage Of Accounts Receivable From Major Customers
PercentageOfAccountsReceivableFromMajorCustomers
0.93
CY2018Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
772000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
572000
CY2018Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2519000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1273000
CY2018Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
600000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
812000
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
127424000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
127874000
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100943000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100952000
CY2018Q1 us-gaap Depreciation
Depreciation
441000
CY2017Q1 us-gaap Depreciation
Depreciation
446000
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10474000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7260000
CY2018Q1 mnkd Current Portion Of Milestone Right Liability
CurrentPortionOfMilestoneRightLiability
1643000
CY2017Q4 mnkd Current Portion Of Milestone Right Liability
CurrentPortionOfMilestoneRightLiability
1643000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
872000
CY2018Q1 mnkd Sales And Marketing Related Expenses Accrued
SalesAndMarketingRelatedExpensesAccrued
625000
CY2018Q1 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
90300000
CY2018Q1 mnkd Customer Discounts And Allowances
CustomerDiscountsAndAllowances
766000
CY2017Q4 mnkd Customer Discounts And Allowances
CustomerDiscountsAndAllowances
873000
CY2017Q4 mnkd Sales And Marketing Related Expenses Accrued
SalesAndMarketingRelatedExpensesAccrued
147000
CY2018Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
362000
CY2017Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
362000
CY2018Q1 us-gaap Interest Payable Current
InterestPayableCurrent
226000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
567000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
962000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
590000
CY2018Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
0
CY2017Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
0
CY2018Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1122000
CY2017Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
714000
CY2018Q1 us-gaap Long Term Debt
LongTermDebt
140269000
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
156822000
CY2015Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
5800000
CY2015Q1 mnkd Payment For Contingent Liabilities
PaymentForContingentLiabilities
10000000
CY2018Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
6000
CY2017Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2018Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
310000
CY2017Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
447000
CY2018Q1 mnkd Note Payable Percentage Of Interest Rate Change
NotePayablePercentageOfInterestRateChange
0.01
CY2018Q1 mnkd Fair Value Of Note Payable To Related Party Description
FairValueOfNotePayableToRelatedPartyDescription
The fair value measurement of the note payable is sensitive to the change in interest rate. If the interest rate changes by approximately 1%, the fair value of the note payable would change by $1 million or 1.4%.
CY2018Q1 mnkd Change In Fair Value Of Note Payable Value Due To Change In Interest Rate Percentage
ChangeInFairValueOfNotePayableValueDueToChangeInInterestRatePercentage
1000000
CY2018Q1 mnkd Change In Fair Value Of Note Payable Percentage Due To Change In Interest Rate Percentage
ChangeInFairValueOfNotePayablePercentageDueToChangeInInterestRatePercentage
0.014
CY2018Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
156600000
CY2018Q1 mnkd Fair Value Of Liability Percentage Decrease
FairValueOfLiabilityPercentageDecrease
0.08
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1943000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1267000
CY2018Q1 mnkd Purchase Obligation Due In Remainder Of Fiscal Year
PurchaseObligationDueInRemainderOfFiscalYear
8900000
CY2018Q1 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
11600000
CY2018Q1 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
15500000
CY2018Q1 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
15500000
CY2018Q1 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
19400000
CY2018Q1 mnkd Purchase Obligation Due In Sixth Year
PurchaseObligationDueInSixthYear
19400000
CY2017Q4 mnkd Purchase Obligation Included In Accounts Payable
PurchaseObligationIncludedInAccountsPayable
1600000
CY2018Q1 mnkd Long Term Purchase Commitment Expiration Date
LongTermPurchaseCommitmentExpirationDate
2023-12-31
CY2018Q1 mnkd Longterm Purchase Commitment Renewal Time Period
LongtermPurchaseCommitmentRenewalTimePeriod
P2Y
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
522000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
947000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
976000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1005000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1035000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
88000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4573000
CY2018Q1 mnkd Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
301000000
CY2018Q1 mnkd Tax Cuts And Jobs Act Of2017 Decrease In Valuation Allowance
TaxCutsAndJobsActOf2017DecreaseInValuationAllowance
301000000
CY2018Q1 mnkd Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0
CY2018Q1 mnkd Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax For Accumulated Foreign Earnings Provisional Income Tax Expense
TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpense
0

Files In Submission

Name View Source Status
0001564590-18-012419-index-headers.html Edgar Link pending
0001564590-18-012419-index.html Edgar Link pending
0001564590-18-012419.txt Edgar Link pending
0001564590-18-012419-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mnkd-10q_20180331.htm Edgar Link pending
mnkd-20180331.xml Edgar Link completed
mnkd-20180331.xsd Edgar Link pending
mnkd-20180331_cal.xml Edgar Link unprocessable
mnkd-20180331_def.xml Edgar Link unprocessable
mnkd-20180331_lab.xml Edgar Link unprocessable
mnkd-20180331_pre.xml Edgar Link unprocessable
mnkd-ex108_456.htm Edgar Link pending
mnkd-ex311_8.htm Edgar Link pending
mnkd-ex312_9.htm Edgar Link pending
mnkd-ex321_7.htm Edgar Link pending
mnkd-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending